Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
While identification of the different molecular signatures and genotypes among responders and non-responders may help develop predictive biomarkers to enable patient stratification in clinical setting, the molecular and genetic heterogeneity in many tumors is still a big challenge for successful cancer therapy [182]
Milani I, Guarisco G, Chinucci M, Gaita C, Leonetti F, Capoccia D
Statements Data availability statement The datasets generated and/or analysed during the current study are not publicly available due to ethical reasons but are available from the corresponding author on reasonable request
No adverse effects were reported, confirming the compounds good tolerability
10.21037/tgh.2019.11.15 107 PowellE
Identification of HRAS mutations and absence of GNAQ or GNA11 mutations in deep penetrating nevi
US$ 21.51
US$ 24.93
US$ 24.48
US$ 25.87
US$ 25.88
